Clinuvel receives IND status

By Kate McDonald
Thursday, 29 January, 2009

Melbourne’s Clinuvel has received investigational new drug (IND) status for its photoprotective drug afamelanotide from the US FDA.

The ruling will allow the company to begin clinical trials in the US. It received orphan drug designation from the FDA in July last year.

Afamelanotide is currently in Phase III trials for the treatment of erythropoietic protoporphyria (EPP) in Europe and Australia, amongst several other trials in UV-related skin disorders.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd